Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
40.96
-0.01 (-0.01%)
May 4, 2026, 11:37 AM EDT - Market open

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
EMPAVELI Revenue
102.45M98.09M
EMPAVELI Revenue Growth
4.44%7.75%
SYFOVRE Revenue
586.93M611.86M
SYFOVRE Revenue Growth
-4.07%122.30%
Total Product Revenue
689.38M709.95M
Total Product Revenue Growth
-2.90%93.83%
Licensing and Other Revenue
314.40M71.41M
Licensing and Other Revenue Growth
340.25%135.61%
Revenue (Other)
-2.00K-
Revenue (Total)
1.00B781.37M
Revenue (Total) Growth
28.46%97.02%
Updated Feb 24, 2026. Data Source: Fiscal.ai.